Spring 2015
Welcome
competitiveness. This issue of ON Highlights showcases some of the folk we are working with to help A warm welcome to our Spring make that happen. We are the ON Highlights, our biannual only membership organisation publication which showcases some in Europe (and perhaps the of the world class business, science world) to have formal relations and technology being undertaken with MassBIO, MassMedic, by our members – as well as BayBIO (just last week renamed a snapshot of the some of the California Life Sciences collaborative work we are doing at Association) and BIOCOM. Do One Nucleus and a roundup of our read about what is happening in main activities at the moment – all the Mass area from the fabulous in one handy place! Dr Susan Windham-Bannister (on pages 5 and 6) and check out One It is clear that the sector is Nucleus plans for BIO (on pages undergoing incredible development 27 and 28). BIO once again sees at the moment. Having witnessed us creating the right platform for the JP Morgan conference at the our members to engage with these start of the year, I now understand important organisations and others why our Business Development via our One Nucleus Dinner and Director Tony returned from the One Nucleus - Stockholm - Uppsala event last year buzzing with Breakfast. Our relationship with the excitement – for months (!) about Flight Centre Business Travel sees the buoyancy and opportunity. I us offering exclusive deals for our felt it too and was so heartened members to travel to and stay at to hear positive noises from our BIO and other key events through members and the wider sector the year. The savings often far about the sound business being outweigh our membership fee! For done there and brought home. With BIO this year we also have exclusive the FierceBiotech Investor Panel tours of New Jersey for our breakfast declaring that the next 5 members, as a result of us hosting years could be the ‘golden age’ of Governor Christie of New Jersey life sciences, it was a cracking start here at our offices back in February. to the year and really set the tone. Our international focus permeates most of what we do. Do check out At One Nucleus we recognise that ON Global (page 37). Since our last you have to do the hard slog, put edition the team has also focused in the hours and travel the world for example on India (my report is to make your business grow. With on page 21) and Switzerland – we that in mind, our mission is to help have a Swiss delegation including our members maximise their global the CEO of Debiopharm visiting us
in early June for a seminar with members. But our focus isn’t entirely overseas facing – we are very mindful of the need for, and importance of, close co-working in the UK. Our Founder Member status of United Life Sciences is something I am especially proud of as it brings tangible benefits to our members – for an update on what this means, or could mean, for you check out page 25. We have also become a Founding Partner of CamNTF – the brilliant new scientific forum based in the area and we have created a formal arrangement with Innovation Forum and a range of other very worthy organisations. We recognise we cannot do everything – but where we can add value, support others who have a like-minded sense of purpose and bring our team expertise to bear for member benefit – we shall do it! The team and I look forward to welcoming you to one of our upcoming events – don’t forget our Summer Social on 30 June and that ON Helix is just around the corner (page 29). The Wellcome Trust Sanger Institute recently became a Partner of ours (see pages 2 to 4) and we are delighted to be the first conference taking place at the new Conference Centre there on 14 July. The artists impressions are amazing!
IN THIS ISSUE
1
The Genome Campus
One Nucleus speaks to our new Partner, the Wellcome Trust Sanger Institute about the past, present and future.
4
Investing in Innovation
Our good friend Dr Susan Windham-Bannister, President and CEO of The Massachusetts Life Sciences Center tells us more.
Mission 22 UK to India
Harriet leads the delegation to Bangalore and Mumbai in February 2015.
2
Spring 2015
Member News
The Genome Campus - A Hub of Biomedical Science and new One Nucleus Partner The Sanger Institute and EMBL-EBI Shared Facility
The Genome Campus is a 125acre estate south of Cambridge in the grounds of Hinxton Hall. Nestled in the quiet countryside of these landscaped gardens, are two world-class research facilities: the Wellcome Trust Sanger Institute and the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI). The Wellcome Trust bought the site in 1994 as a home for the new Sanger Centre. Since then the site has developed to become a British hub of biomedical science.
the Wellcome Genome Campus, an estate 11 miles south of Cambridge, next to the village of Hinxton. Our mission is ‘to advance understanding of the biology of humans and pathogens using genome sequences in order to improve human health’, which put simply means that all our research goes towards understanding genomes in health and disease.
One Nucleus speaks to Julia Wilson (JW), the Sanger Institute’s Associate Director of External Relations, and Adrian Ibrahim (AI), the Institute’s Head of Technology Transfer and Business Development.
We have a core faculty of 40 and a further 12 Associate Faculty and two International Fellows. Faculty are spread across six programmes of research - Human Genetics, Cancer, Computational Genetics, Pathogen Genetics, Cellular Genetics and Malaria.
the institute relatively unique, only matched by a few other research institutes in the world. So we have economies of scale and activities that can be effectively planned and delivered, our major core facilities are managed centrally including DNA Pipelines, Animal Facility, and Cellular Genetics and Phenotyping. We also have smaller core facilities for Protein Mass Spectrometry, Fluorescence Activated Cell Sorting
‘All our research goes towards understanding genomes in health and disease.’ and Cytogenetics together with a new facility for Single Cell Genomics.
The Sanger Institute has a strong tradition of initiating and developing databases which curate, organise Tell us about the Wellcome and present data to the research Trust Sanger Institute and the community. Under our Data Sharing type of science you are involved in. The Sanger Institute’s research policy, data is released either portfolio is defined by its large scale, via open (without restriction) or [JW] The Sanger Institute is a high throughput data production managed (release is conditional) Genome Institute located on and analysis platforms, making access. www.onenucleus.com
Member News
Spring 2015
Julia Wilson, Associate Director of External Relations, Sanger Institute
maintain a position at the forefront of biomedical research. The Sanger Institute sits at the centre of a network of science, with collaborations with other scientists and academic institutions. We have strategic partnerships with the EMBL-EBI, the University of Cambridge and the Francis Crick Institute. The Sanger Institute
How do you see the future? [JW] Our future is all about genomics and genome variation in humans and pathogens and translating these scientific advances into healthcare benefits. In addition to collaborating with academics and commercial parties we engage the wider influencing
‘Our commitment to enabling healthcare benefit in this era of clinical genomics has catalysed a diversification of the campus to accommodate industrial partners.’ How did the Sanger Institute contribute to the Human Genome project and how has that shaped the institute today? [JW] Since our inception in 1993 the Sanger Institute has participated in some of the most important advances in genomic research. The Institute made a major contribution to the Human Genome Project, sequencing one third of the human genome, the largest overall contribution. Since then we have developed our science to make further achievements in the understanding of genetics in health and disease and expanded to
also leads or is involved with several multi-institutional networks and consortia, for example the International Cancer Genome Consortium, 1000 Genomes Project, and the UK10K Project. We also consider human health globally; this ranges from understanding the genomics of neglected tropical pathogens, understanding outbreaks of disease to capacity building and understanding the genomics of emerging non-communicable diseases in low and middle income countries.
community to inform, shape and develop opinion on the importance and impact of genomics research. we are a partner organisation in a prospective Parliamentary AllParty Group (APG) aimed at helping politicians to understand and realise the health benefits of UK investment and excellence in science and technology. Together with the EMBL-EBI we are working to shape the international landscape of genomics research and application through engaging and leading international coalitions such as the Global Alliance for Genomics and Health to enable interoperability
Aerial shot of the Wellcome Genome Campus
(Continued on page 4) www.onenucleus.com
3
4
Spring 2015
Member News
Adrian Ibrahim, Head of Technology Transfer and Business Development at the Sanger Institute
of diagnostics and therapeutics. To promote cross organisational collaboration the Sanger Institute has developed a strong Associate Faculty programme that enables world leading researchers’ access to the Sanger Institute’s knowledgebase and infrastructure.
What campus services and facilities, now and in the future, could be of interest to One Nucleus members?
[AI] Our commitment to enabling healthcare benefit in this era of clinical genomics has catalysed a diversification of the campus to Both EMBL-EBI and the Sanger accommodate industrial partners. Institute are increasingly engaging What is clear is that these partners, with industry to ensure that in addition to the association with our exceptional capabilities are the Genome Campus brand, want leveraged to deliver healthcare access to the knowledge and benefit. This was typified by infrastructure situated here. We’re the creation of the Centre for talking primarily about the compute Therapeutic Target Validation capability, sequencing and various for sharing of genomic and clinical (CTTV) in 2014, an open innovation high throughput experimental data. collaboration that aims to provide an platforms that operate at the R&D framework that applies to all Sanger Institute and EMBL-EBI. We’re also excited about the aspects of human disease. Initiated Genomics England initiative and as a three way collaboration The Sanger Institute launched welcome the commitment to between EMBL-EBI, the Sanger two companies last year in the understanding genomic science Institute and GSK, CTTV is now rare disease and cancer fields to improve the future of genomic speaking to prospective partners. respectively and is seeking to medicine. Use of genome variation support them in the early stages. is already used in some sectors The new Biodata Innovation In a sense we’re learning together of medicine, in the diagnosis and Centre (BIC) is due to open on and developing a more service management of inherited genetic campus in May 2016 - tell us oriented approach to delivering diseases and cancer. Increasingly more. our facilities to third parties. We’re scientists with clinical experience or already planning to establish more clinicians with genomics experience [AI] The decreasing cost and wet and dry space to meet the will be invaluable when using an increasing throughput of sequencing needs of companies not just in the individual’s genomic profile to shape technologies has created new Cambridge area, but nationally clinical decisions. opportunities to apply the scientific and internationally. But the outputs of genomics and informatics campus is much more than the The Genome Campus is home to research. The Sanger Institute has exceptional scientific facilities. We the Sanger Institute and EMBLrecognised a need to offer bespoke have fantastic lecture programmes EBI - how does the site work as facilities to innovative companies and are significantly expanding a hub of biomedical science? that provides access to the rich our conferences and courses resources of the Wellcome Genome programme which is already heavily [AI] The Sanger Institute and Campus. subscribed to. From a family EMBL-EBI are highly synergistic. perspective there’s an outstanding Our collective core competencies The first stage in accommodating nursery, transport to and from the create a world leading genomics commercial entities is creation site, good catering facilities and and bioinformatics centre within of the BIC. It will house over excellent sports facilities. the largest bio cluster in Europe, 200 people ranging from one at a time when generation and man start-ups to larger, more For further information visit: interpretation of large datasets established companies. The BIC www.sanger.ac.uk/about/campus/ is regarded as key to addressing will be a dry building, focussed on a diverse array of unmet medical informatics activities in a stateneeds. of-the art setting. We’ve been really encouraged by the level of Both organisations are very interest from both companies and collaborative, recognising the the broader biomedical community importance of integrating basic including investors who are eager to and clinical research together with see a genomics/informatics cluster the industrial expertise required develop here at Hinxton. for the discovery and development www.onenucleus.com
Member News
Spring 2015
Hot off the Press Mass News: Investing in the State of Innovation Dr Susan Windham-Bannister, President and CEO, MLSC
The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialisation. One Nucleus talks to Dr Susan WindhamBannister, the Center’s first President and CEO, as she prepares to step-down from her seven year tenure.
‘To date the MLSC has invested or committed more than $590 million in public funding, leveraging $1.7 billion in third-party investment and creating thousands of jobs.’ Massachusetts has emerged as the world’s leading ecosystem for life sciences innovation and growth. As the founding President and CEO, my job was to take the vision represented by the Initiative and turn it into a high-functioning and impactful organisation. I was the ‘architect’ and had to create this entity from scratch – to develop a strategy and a brand and to find the talented people I would need to help me achieve this goal. Over the past seven years this team has created a portfolio of programs that are enabling and accelerating life sciences innovation, product development and commercialisation in Massachusetts.
Because of my doctoral training in health policy and my professional background as a consultant to the life sciences industry, I was able to really be bilingual in this job – I could understand my business Tell us a little about the MLSC stakeholders and their strategic and your role as CEO and needs, and I was also able to President. address the needs of policymakers for fair distribution of resources and The MLSC is a quasi-public agency economic benefits. As an Africancharged with implementing the 10- American woman I also recognised year $1 billion life science initiative the importance of inclusion and enacted by our State Legislature diversity in the life sciences and signed into law in 2008. To workforce and have targeted these date the MLSC has invested or issues. I want all socio-demographic committed more than $590 million groups to have equal opportunities in public funding, leveraging $1.7 and to be able to successfully billion in third-party investment and compete for jobs in the 21st century creating thousands of jobs. Thanks innovation economy. in large part to these investments, Massachusetts now has more people working in the life sciences percapita than any other US state, and over the past seven years
How is the initiative progressing? After nearly seven years of strategic investment, Massachusetts has emerged as the global leader in life sciences and has become a magnet for companies large and small from the rest of the US and from all over the world. Earlier this year, Genetic Engineering and Biotechnology News (GEN) ranked Massachusetts’ biopharma cluster #1 in the US. All of the world’s top 10 biopharmaceutical firms now maintain facilities here, along with over 500 other biopharma companies and more than 400 medical device makers! According to research conducted by Dr Barry Bluestone and Dr Alan Clayton-Matthews at Northeastern University, since the enactment of the life sciences initiative in 2008 the life sciences sectors have become the fastest job creating sectors in the Massachusetts economy. This has not happened by accident – it has come as the result of a focused investment strategy. I will be stepping down from my position as President and CEO of the MLSC at the end of May, but I know I am leaving the Center in good hands. With its strong Board of Directors, committed outside scientific advisers and talented staff, I am certain that the MLSC will continue to innovate and invest strategically to ensure that Massachusetts maintains and strengthens its position of global leadership in the life sciences. (Continued on page 6) www.onenucleus.com
5
6
Spring 2015
Member News
Dr Susan Windham-Bannister with Massachusetts Neuroscience Consortium funding awardees
What are the challenges for By providing funding to premier MLSC and for global life sciences academic research teams in the innovation in general? state, the Consortium aims to introduce academic researchers to The challenge is to move the ball the challenges of applied research, forward on the development of facilitate industry-academic treatments, therapies and cures in collaborations and accelerate areas where the need is great but the discovery of promising drug progress has been elusive. One such candidates. area is neuroscience, specifically in addressing diseases such as The MLSC launched the Alzheimer’s, ALS and Parkinson’s. Massachusetts Neuroscience To address this challenge new Consortium based on our belief that
‘The challenge is to move the ball forward on the development of treatments, therapies and cures in areas where the need is great but progress has been elusive.’ approaches to innovation are needed, including new models for collaboration. Founded in the summer of 2012 and administered by the MLSC, the Massachusetts Neuroscience Consortium is a pioneering new model that is designed to leverage Massachusetts’ rich environment of neurobiology and neuroscience. Founding members included AbbVie, Biogen Idec, EMD Serono, Janssen Research & Development, LLC, Merck, Pfizer and Sunovion Pharmaceuticals Inc. The Consortium’s purpose is to accelerate early-stage neuroscience research available to the pharmaceutical industry. www.onenucleus.com
and must be shared. No country or region can address the challenges of new discovery and development alone, as the challenges we face in trying to improve global health are too great. One of the most important goals in our work has always been to turn Massachusetts into a laboratory for new models of collaboration that will significantly improve the pace, efficiency and success rates of innovation. With this in mind we have created several programs and tools to foster global partnerships in life sciences.
UP was announced at BIO 2014 in San Diego and it is our newest international program. The program opens doors to R&D collaboration companies working together will between Massachusetts companies, make faster and more significant and research partners in any progress in developing breakthrough country around the world. Projects treatments or even cures. We will typically last up to one year believe that collaboration is vital to and will focus on a specific R&D life sciences innovation, where 1+1 milestone within the context of an truly equals eleven. One Nucleus overall project. Up to $1 million members can learn more about the is available for the current fiscal Consortium here: year to fund grants of $50,000 www.masslifesciences.com/ (minimum) to $200,000 (maximum) programs/neurosci for selected life science projects. Readers can learn more on the Tell us about the UP Program MLSC website at and the potential opportunities www.masslifesciences.com that exist for One Nucleus members At the MLSC we believe that knowledge and expertise are being developed all around the world,
Member News
Spring 2015
News from the Babraham Research Campus Babraham Institute Hal at Babraham Research Campus
and aimed to encourage academicindustrial collaborations.
Babraham Bioscience Technologies (BBT) and the Biotechnology and Biological Sciences Research Council (BBSRC) announced earlier in the year the signing of a longterm lease with Imperial College for the development of a new facility designed to support spinout and scale-up companies at the Babraham Research Campus. The first tenant will be Abzena plc, a pharmaceutical firm already based at Babraham. Derek Jones, BBT Chief Executive, added: ‘Imperial College building a facility on the campus strengthens the pre-eminent position of the Babraham Research Campus in the Cambridge bio cluster and provides opportunities for Imperial College spin-outs and established regional companies to work together. It
The Institute’s Epigenetics programme is amongst the world’s ten leading epigenetic research centres. The event featured a morning of talks by Group Leaders within the Epigenetics programme and also a talk from Dr Jason Mellad from Cambridge Epigenetix Ltd. (www.cambridge-epigenetix.com) exemplifying how the Institute works with industry. The next symposium will be held on 11 November 2015 and will present the Institute’s immunology research Professor Michael Wakelam, Director programme (www.babraham.ac.uk/ our-research/lymphocyte) followed of the Babraham Institute, said: ‘As an academic community we are by a networking lunch and poster session. The programme’s group delighted to have the opportunity leaders will also be available for to welcome Imperial College to 1:1 meetings to explore areas of Babraham and look forward to shared interest. Please email kec@ exploring how to maximise the engagement between our scientists babraham.ac.uk to express an interest in registering for this event. and those in the College in order to build upon our research into BBT: www.babraham.co.uk understanding lifelong health and Babraham Institute: well-being.’ www.babraham.ac.uk BBSRC: www.bbsrc.ac.uk Science Symposiums for Industry really is a step-change for the campus.’
The Babraham Institute hosted a free science symposium event on Thursday 14 May which focused on the Institute’s epigenetics research programme (www.babraham. ac.uk/our-research/epigenetics)
The Cambridge Phenomenon Cambridge Phenomenon was established in 2009 by Charles Cotton to celebrate the many facets of Cambridge’s unique information technology, bioscience and medical cluster. Now known as Cambridge Phenomenon International, it currently works to promote the Cambridge technology cluster to the wider world.
a first book, The Cambridge Phenomenon 50 Years of Innovation and Enterprise, which told the stories of the cluster of high-tech companies in the Cambridge area and the people behind them, from the perspective of the entrepreneur. A Mandarin version of this book will be launched in China, shortly.
Last year, the pair decided that In 2012, Charles and Kate Kirk, a the next book - The Cambridge writer and freelance editor, launched Phenomenon: Global Impact - would
explore the many ways in which Cambridge technologies, Cambridge companies and Cambridge entrepreneurs have improved the lives of people around the world. Writing from own experiences, the authors know that the extraordinary range of Cambridge achievements is often lost to public view because so much of what comes out of Cambridge goes into helping other businesses succeed. (Continued on page 8) www.onenucleus.com
7
8
Spring 2015
Member News From a small city of around 120,000 people, Cambridge Life Science and Healthcare companies make a big impact on the world. Examples of this include Humira, a treatment for rheumatoid arthritis, which originated from Cambridge Antibody Technology and according to IMS Health was the world’s bestselling drug in 2014; Lemtrada, a breakthrough drug for multiple sclerosis; gene sequencing machines based on technology from Solexa; and Horizon Discovery whose 2014 listing was an all-time record for a life science company on AIM.
One Nucleus CEO, Harriet Fear who sits on the Cambridge Phenomenon Advisory Board, commented: ‘The latest book written by Kate Kirk and Charles Cotton of Cambridge Phenomenon is a great opportunity to promote Cambridge on the world stage and I encourage One Nucleus members to support the book and be part of the story.’ To order securely online visit: www.tmiltd.com/globalimpact
Crown’s Leading Translational Oncology Services Concept of a HuTrial - An Avatar Clinical Trial
Crown Bioscience (Crown) recently positioned itself as the leading provider of translational oncology drug discovery services with the acquisition of Molecular Response’s patient-derived xenograft (PDX) model library and service operations. The acquisition also covered 8,000 viable cryopreserved, www.onenucleus.com
100% US tumour samples for model development from the 140,000 samples available in Molecular Response’s tumour bank, with the option to further select and develop models from the wider collection.
regimen. This means patients can be selected for recruitment to clinical trials by genetic signature and clinical trial design can be better informed to reduce attrition in the clinic.
Incorporating the newly acquired models, the Crown collection of >1,600 PDX is the world’s largest and most comprehensive collection. It provides a highly diverse demographic covering patient populations from North America, Asia, and Europe, spanning over 70 clinical diagnoses. The models include multiple stages of cancer development and are representative of patients that are treatment naïve as well as those who have received prior treatment. This provides a 360 degree view of cancer making Crown’s collection truly representative of the oncology patient population.
Crown continues to invest in acquiring assets, expertise, and facilities with the Molecular Response site in San Diego now designated a global Centre of Excellence for Translational Oncology. In conjunction with Crown’s recent expansions in the UK and Kannapolis, North Carolina as well as existing operations in Beijing and Shanghai, the company provides local expertise to support clients worldwide and delivers the most comprehensive suite of expertise, models, services, and locations for drug discovery available in the world today.
The size of and capacity of Crown’s collection allows avatar clinical trials (HuTrials) to be performed in months rather than years to understand the pharmacology and efficacy across a clinically relevant population and identify the genetic signature of responders versus nonresponders to a particular treatment
For more information visit: www.crownbio.com
Member News
Spring 2015
A Stellar Year for F-Star John Haurum, CEO, F-Star
For F-star, a company developing novel bispecific antibodies, the past 12 months have been transformational. Bispecific antibodies can deliver novel therapies by binding to two targets concurrently. F-star, based at the Babraham Research Campus, creates bispecific antibodies by modifying the constant region of an antibody and is the only company able to use this approach. Its Modular Antibody Technology provides the ability to rapidly explore many
new target combinations, identify those with greatest potential, and then readily develop these bispecific antibodies due to their favourable drug properties. As well as having innovative science, F-star has established an innovative company structure using assetcentric vehicles to accelerate the development of a pipeline of proprietary therapeutics. This structure enables greater commercial and financial flexibility for the company and future partners.
announced the initiation of a phase 1 clinical study of FS102. F-star’s second asset centric vehicle, F-star Beta, was established in November last year to develop oncology and immuno-oncology compounds. Since then a significant deal with a global pharma partner in the immuno-oncology space has also been completed.
F-star is continuing to make significant progress with developing its pipeline of novel bispecific antibody products and has recently In October last year, F-star entered expanded its therapy area focus into an agreement that provided from immuno-oncology to all Bristol-Myers Squibb the exclusive immunology-related diseases. The option to acquire F-star’s first asset- next 12 months promise to be just centric vehicle, F-star Alpha Ltd, as exciting for F-star as the last and gain worldwide rights to its year. lead asset FS102. FS102 is a novel Human Epidermal growth factor For further information visit: Receptor 2 (HER2)-targeted therapy www.f-star.com in development for the treatment of breast and gastric cancer. BMS made an initial payment of $50 million and the total aggregate consideration may reach $475 million. In January this year F-star
Heptares Acquired by Sosei GPCR with bound drug in membrane
Heptares will become a wholly owned subsidiary of the Group with its existing R&D operations continuing in the UK at the BioPark in Welwyn Garden City. Heptares is bringing its world-class science and drug discovery capabilities to the Group and will contribute a stream of new products derived from its unique StaR technology platform and structure-based drug design approach.
Heptares Therapeutics (Heptares), a clinical-stage UK company creating novel medicines targeting G protein-coupled receptors (GPCRs), announced in February that is
has been acquired for up to $400 million by Sosei Group Corporation, a Japanese biopharmaceutical company with operations in Japan and the UK.
While a core part of Sosei’s future, as an independent subsidiary, Heptares will maintain the culture and business model which has been the foundation of its success so far while benefiting from significant investment into its technology and pipeline into the future. (Continued on page 10) www.onenucleus.com
9
10 Member News Heptares will continue to advance its pipeline of novel, differentiated candidates focused on highly validated targets in neuroscience, metabolic and orphan disease areas. These include a first-in-class M1 agonist in clinical development to treat cognitive impairment in Alzheimer’s disease, schizophrenia and other disorders. Other pipeline highlights include a novel A2A antagonist in development for ADHD and further products targeting multiple high-value CNS conditions.
Spring 2015 Heptares will also continue to progress partnerships with a number of the world’s leading pharmaceutical and biologics companies. The quality of the Company’s science and GPCR drug discovery capabilities have led to partnerships with AstraZeneca/ MedImmune, Cubist (Merck), Takeda and MorphoSys.
respiratory products (Ultibro Breezhaler and Seebri Breezhaler) marketed by its partner Novartis, sustainable drug discovery and clinical development capabilities for generating innovative medicines and a broad and balanced pipeline with strong growth prospects. For more information visit: www.heptares.com
The Company’s combination with Sosei creates a global biopharmaceutical group with growing revenue streams from
A Year of Transformational Change for Horizon Dr Darrin Disley, CEO, Horizon Discovery
For Horizon Discovery Group (Horizon), the last year has reportedly been outstanding, with product and service revenues up 99% and gross margin increasing to 55%. The company says it is ‘well positioned for the next stage of accelerated growth’.
new e-Commerce and ERP systems group-wide that will deliver long term value. We will also continue to leverage additional non-organic (milestone) value in our research business over the coming years. We remain committed to continuing to deliver innovative products, services and research and are Dr. Darrin Disley, Horizon’s CEO and excited about our prospects for the President, commented: ‘Horizon’s future.’ strong year of growth underpins the Group’s position as a leader During 2014 Horizon saw rapid in the field of genome editing and growth and transformational personalised medicine. Looking change, transitioning from a private ahead, we plan further investments UK life science business employing in the scaling of our products and 74 staff on a single 18,000 sq. ft. services businesses including the site in Cambridge to a publiclydevelopment and implementation of listed international life science www.onenucleus.com
group employing 183 staff across 84,000 sq. ft. of facilities located in Cambridge (UK), Boston (USA), St Louis (USA) and Boyertown (USA), and then in early 2015 adding a facility in Vienna (Austria). Horizon’s technology platforms, products and services are being used by an increasing number of academic, biotechnology, diagnostic and pharmaceutical customers, and its customer base grew by 171% in 2014, to 955 in total in around 50 countries, including 30 of the top 50 global pharmaceutical companies. In March of this year, Horizon announced that it will be providing genomic Reference Materials to support Phase Two of Cancer Research UK's Stratified Medicine Programme. Horizon says it believes that its work with next generation sequencing could help improve survival rates of lung cancer, which are still too low and with limited treatment options. For more information visit: www.horizondiscovery.com
Spring 2015 11
Member News
Easily Establish a Presence in the United States Rob Johnson, Founder, Foothold America
finding the right person can be an issue. Added to this, several states, including the leading biotech hubs, Massachusetts and California, have very strict employee-contractor laws which, for example, make it almost impossible to have an independent contractor relationship for business development purposes. This often means the only option is to form a legal entity in the US in order to employ a worker – this brings high cost, management distraction, and the significant challenge of navigating US bureaucracy.
The US is a critical market for all life science companies, and many UK companies would benefit from having a presence there. Building and maintaining business relationships with American companies not only requires long term commitment, but also considerable expense as well as travel time to the US. Many companies look to work with local independent consultants, but
To overcome these barriers to doing business, Foothold America has recently been launched as a service that makes it much easier for UK companies to establish a presence in the US. The service has been developed by Alacrita, a Cambridgebased life science consulting firm with offices in the US, in association with the British Consulate in Boston. Alacrita works with the UK company to develop a job description, advertise the position and select the best candidate. It
hires the employee and provides the relevant HR services (including medical insurance); thus, removing any bureaucratic burden. Whilst the employee works on a dedicated basis for the UK company, they benefit from Alacrita’s resources, networks and relationships in the US as well as feeling part of a local team. Remaining very flexible, the relationship can be terminated with one to two weeks’ notice. Since its launch last summer, four UK life science companies are working with Foothold America. To find out more, visit: www.footholdamerica.com or email Rob Johnson, a Partner of Alacrita in Boston, on rjohnson@alacrita.com
Uncovering Promising Drugs in Pharma Libraries charity and One Nucleus member, MRC Technology, will identify promising drug projects that are no longer in development by the industry and help scientists to take them forward to the next stage, before returning them to pharmaceutical companies for further development into marketable treatments. A global coalition of charities and funding bodies has been formed recently to restart the development of promising drug candidates for neurodegenerative conditions
such as dementia, motor neurone disease and Parkinson’s disease. The Neurodegeneration Medicines Acceleration Programme (NeuroMAP), led by medical research
It is estimated that over 50 million people worldwide currently live with neurodegenerative diseases. However, research into these conditions is complex, expensive (Continued on page 12)
www.onenucleus.com
12 Member News and has a high failure rate due to the complexity of brain and nervous system function. This means that pharmaceutical companies that may have promising drug candidates at an early stage of development have to side line them and turn their attention to more favourable research areas. With the number of people living with neurodegenerative conditions set to rise substantially during the next few decades, and too few treatments available to stop the progression of many brain disorders, there is an urgent need to revive research and development for both relatively common and rare brain and central nervous system disorders. As a coalition of nine charities and funders, Neuro-MAP will help ensure that the potential of fundamental early stage research
Spring 2015 into neurodegenerative disease is realised, and promising drug candidates taken forward towards clinical testing. It will also look to repurpose existing drugs and compounds for other conditions, for example, the use of hypertension drugs for the treatment of vascular dementia. The programme protects both charities’ and pharma’s investment and allows charities to maximise their impact on patient’s quality of life.
and destructive diseases. This is an amazing opportunity to accelerate the next generation of neurodegenerative drugs towards the patient and improve their quality of life.’ Partners in the Neuro–MAP are: Alzheimer’s Association US, Alzheimer Research UK, Alzheimer’s Society UK, ALS Association, Michael J Fox Foundation, MND Association, MRC Technology, Northern Health Science Alliance and Parkinson’s UK.
Mike Johnson, Director of Corporate Partnerships at MRC Technology The website for the programme is said: ‘We’re pleased to be able www.medicinesaccelerationprogram. to use our unique position at org the centre of charities, funders, academia and industry to bring together the right combination of funding, skills and capabilities to really make a difference for patients living with these debilitating
Cambridge New Therapeutics Forum: One Nucleus is a Founding Partner
The purpose of CamNTF is to promote interactions between people who do not normally meet each other, and this first meeting was a tremendous success, with 80 attendees from the university, local biotech and pharma firms, the European Bioinformatics Institute, and the Wellcome Trust Sanger Institute. The meeting opened with a fascinating talk by Mene Pangalos, who leads AZ’s Innovative Medicines Unit: Mene walked the audience through the drug development www.onenucleus.com
process, with specific examples from AZ’s pipeline, and discussed strategies for drug discovery. Next up was Jane Osbourn, AZ’s VP for Research and Development, and site leader for MedImmune. Jane discussed the use of display technologies such as phage display for drug development and highlighted the tremendous increases in efficiency of these technologies over the past decade. Following these talks the audience retired to MedImmune’s airy atrium for an hour of drinks, nibbles, and networking. Experienced networkers exchanged numerous business cards, while younger participants pinged each other’s phones. Overall, the evening was a great success. The latest CamNTF meeting was held on 28 April at the Babraham Institute. The next meeting is being held at
EMBL-EBI on 18 June. For more information visit: www.onenucleus.com/cambridgenew-therapeutics-forum Delegates gathering for the first CamNTF meeting hosted by MedImmune
AstraZeneca (AZ) hosted the inaugural meeting of the Cambridge New Therapeutics Forum (CamNTF) on the evening of 2 March at the MedImmune complex in Granta Park. CamNTF is a scientific forum for scientists, particularly young scientists, in the Cambridge area who are interested in the development of new therapeutics.
Spring 2015 13
Member News
Stevenage Bioscience Catalyst – A Campus Full of Opportunity Stevenage Bioscience Catalyst
With spring having sprung at Stevenage Bioscience Catalyst (SBC) the open innovation campus continues to flourish. Over the past year it has seen the bioincubator brimming with exciting and innovative companies, including Tokyo Electron, Puridify, Antikor and Ossianix, to name just a few. The campus’ academic community from University College London (UCL) and the University of Cambridge numbers over 30 researchers. In the last month UCL completed the migration of a further two projects from Applied Biomedical Engineering and Inflammation and Tissue Repair to SBC.
Recently, it was announced that the Cell Therapy Catapult is to build a £55M cell-manufacturing centre at Stevenage. The opening of the centre is scheduled for 2017 and it will provide state-of-the-art manufacturing for late phase clinical trials and supply of advanced therapeutics. The combination of expertise within SBCs SME community, GSK Cell and Gene therapy research teams and the Cell Therapy Catapult Manufacturing Centre will undoubtedly provide an internationally renowned site, fertile for inward investment into the sector and the U.K. The team are now onsite and working with SBC to begin construction later this year. Last year marked the launch
of SBC’s first research funding call with the Open Innovation Challenge in Neurodegenerative Disease. A competition designed to catalyse research, which may not otherwise happen and forge new collaborative projects across the UK. In conjunction with MIMIT* and our funding partners (Astex Pharmaceuticals, Alzheimer’s Research UK, Eli Lilly, GE Healthcare Life Sciences and GSK) SBC will be making awards to six projects within five of the academic health science centres in the UK. The teams will be focusing on biomarkers for diagnosis and stratification and the role of inflammation in neurodegeneration. Stevenage Bioscience Catalyst (SBC) is a One Nucleus Partner. To find out more visit: www.stevenagecatalyst.com *MIMIT (Manchester: Integrating Medicine and Innovative Technology), forms a cornerstone of Manchester Academic Health Science Centre (MAHSC) Health Technology Hub.
Identifying New Druggable Targets for Therapeutics In April, PhoreMost, a biopharmaceutical company focused on increasing the diversity and affordability of novel therapeutics, was founded to identify new druggable targets for cancer and other unmet diseases. Based in Cambridge, PhoreMost successfully raised £2.5 million ($3.8 million) in Seed-funding from Cambridgebased Angels; Jonathan Milner,
Amadeus Capital, Sunil Shah and Prashant Shah (O2H Ventures), Cambridge Enterprise, and Dr Chris Torrance, PhoreMost’s CEO. The funding will be used to build commercial operations based on a new drug discovery platform developed by the laboratory of Ashok Venkitaraman at Cambridge University, that can unmask cryptic drug-sites in key disease targets
and pathways currently considered ‘undruggable’ by the pharmaceutical industry. Due to advances in the speed and cost of sequencing the human genome, a diverse array of potential targets to attack cancer and other complex diseases have now been defined. However, using conventional pharmaceutical (Continued on page 14) www.onenucleus.com
14 Member News
Spring 2015
Dr Chris Torrance, CEO, PhoreMost
approaches, the majority of these targets are therapeutically inaccessible, or undruggable, at this time. Based on PhoreMost’s proprietary Protein Interference technology, the company has developed Site-Seeker, a nextgeneration phenotypic screening platform that can identify the best new targets for drug development and, crucially, how to drug them. Using Site-Seeker, PhoreMost has identified drug candidates to a novel synthetic-lethal target for KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), and is soliciting collaborative partners for further development.
effective range of new ‘precision medicines’. The technical key to this goal is to focus and accelerate the development of novel drugs towards the most impacting disease targets. However, these are difficult to define upfront and invariably hardto-drug using conventional drug design technologies once known. Site-Seeker has been developed to address both of these current bottlenecks in drug discovery, and thus potentially open up many new therapeutic avenues for a range of intractable diseases in the future.’ For more information visit: www.phoremost.com
Dr Torrance commented: ‘We are thrilled to have the backing of investors who share our passion to more efficiently translate advances in human genetics into a more
Intertek Opens New GMP Pharmaceutical Stability Storage Facilities this Week Intertek pharmaceutical stability storage facility in Royston
new GMP compliant facility will enable clients globally to establish recommended and bespoke storage conditions with a state-of-the-art environmental monitoring system.
Intertek, the leading quality solutions provider, has opened a new 8,000 ft², 190,000 litre pharmaceutical stability storage facility in Royston, UK, in response to increased client demand and enabling the company to broaden the range of solutions it can offer to the global pharmaceutical industry. www.onenucleus.com
Mark Hammond, Laboratory Director, shared ‘This new facility, integrated with our scientists’ experience and knowledge of pharmaceutical testing, will bring a range of storage solutions with options for client bespoke conditions and risk management storage to meet the increased demands from our global clients.’
The new facility is part of a wider investment programme in Intertek’s global pharmaceutical capabilities and complements the company’s existing product development services for pharmaceuticals, consumer healthcare, biologics, medical devices and nutraceuticals both in Melbourn and globally. This
Chetan Parmar, Senior Vice President of Intertek Life Sciences added ‘With over 20 years of experience in the design and management of pharmaceutical stability studies, Intertek’s new facility will benefit our clients through a truly flexible stability outsourcing partnership.’ Harriet Fear, CEO of One Nucleus (Continued on page 15)
Spring 2015 15
Member News said: ‘Research and development lie at the heart of the pharmaceutical industry, which invests more than any other industrial sector in the UK, with up to approximately £11.5 million spent every day. It is great to see that Intertek is supporting global clients in their research and development by investing in this impressive stability storage facility in the heart of Europe’s largest life science and healthcare cluster.’
Intertek UK & Eire Chief Executive Rob van Dorp said; ‘Intertek has over 20 years of experience in analytical testing and formulation for the inhaled products behind treatments for Asthma, Cystic Fibrosis, Diabetes, and Chronic Obstructive Pulmonary disease and has built a reputation for providing outstanding and responsive customer service for challenging pharmaceutical developments programs. The team are therefore
well placed to expand the range of solutions they can provide for clients who are developing ever more complex products.’ Visit: www.intertek.com
Endomag Opens Two New Offices Due to Rapid Expansion Endomag’s new headquarters in the prestigious Jeffreys Building, St John’s Innovation Park
The cancer healthcare company Endomag has relocated its Cambridge headquarters to larger offices in the prestigious Jeffreys Building, St John’s Innovation Park, due to its rapid growth this year.
also developing a unique platform of devices that spans from the Sentimag and Sienna+ system supporting diagnostics into systems for therapeutics following acquisition of the ACT portfolio last year.
Endomag has also opened its new US office in Austin, Texas, in preparation for expansion into the American market.
Dr Eric Mayes, CEO at Endomag, said: ‘We revealed our new brand identity recently, and the new offices in both the UK and the US reflect a time of exciting change for Endomag as we look to expand into global markets.
The company has recently started a US trial of its Sentimag and Sienna+ system for staging breast cancer and is expecting significant continued growth through international sales expansion. It is
a new chapter for Endomag as we take significant strategic steps in the development of our products. We believe the use of magnetics to support minimally invasive treatments has huge potential and we’re confident that our product platform offers simple and accessible solutions in cancer care.’ For further information visit: www.endomagnetics.com
‘We’re looking forward to settling into our new premises, which has its own development lab, and starting www.onenucleus.com
16 Member News
Spring 2015
LabCorp and Covance Join Forces in Global Healthcare Diagnostics LabCorp recently acquired Covance to create a world leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end solutions for drug and diagnostics development and commercialisation.
of LabCorp, we will employ our capabilities to enhance drug development, diagnostic services and the delivery of healthcare to better address the system’s demand for improved outcomes at lower costs.’
‘We are excited to bring two industry leaders together to provide a unique and complete set of services that will benefit all healthcare stakeholders,’ said David P. King, Chairman and Chief Executive Officer of LabCorp. ‘Our complementary services and capabilities will enable us to pursue multiple strategic opportunities in both the clinical laboratory and drug development businesses. I have worked closely with the Covance team since November and am impressed with their talents and scientific expertise. Combined with the enormously talented people
The combined company’s headquarters are located in Burlington, North Carolina. Covance Drug Development will continue to operate under the Covance name, with its headquarters in Princeton, New Jersey. Together, LabCorp and Covance have more than 48,000 employees worldwide. Covance is a leading drug development services company providing a wide range of earlystage and late-stage product development services on a worldwide basis primarily to the
pharmaceutical and biotechnology industries. Including LabCorp’s leading network of primary and specialty laboratories, Covance provides more than 4,500 laboratory tests, ranging from routine blood analyses to reproductive genetics to companion diagnostics, in addition to tests for the chemical, agrochemical, and food industries. Covance is one of the few drug development companies capable of providing comprehensive global product development services. Together, Covance and LabCorp maintain offices in more than 60 countries. For more information visit: www.covance.com
A New UK Life Sciences Web Portal A new UK Life Sciences web portal - biotechnology markets. One funding for science, engineering and www.lifesciences.ukti.gov.uk Nucleus is one of the data manufacturing activities available to - has been launched to provide a partners who has been the health life sciences sector. single access point to the UK Life instrumental in providing this Sciences landscape. It provides company information. There is a Latest News section that an online platform to allow UK provides a collective news forum and international companies, Users are able to perform one for UK life sciences. A monthly associations, academia and R&D company search before being asked e-newsletter will be published with organisations to connect. to register on the site. Registration all of the main stories circulated allows continued access to all to registered users of the site; The initiative is led by UK Trade & of the benefits of the site and is sign-up for the e-newsletter is Investment (UKTI) Life Sciences simple to complete. Another key via the home page. For those Organisation (LSO) and the feature is the Access to Funding interested in investing in the UK Office for Life Sciences (OLS) – in tool that highlights Government or exporting from the UK, there is collaboration with data partners, the opportunity to request more stakeholders and industry. One information through a Contact of the key features of the site is Us option. Under the Contact Us access to a database of nearly section, UK companies are featured 5,000 UK life science companies on request and have the facility to that are developing, producing provide updates to their profiles. and marketing products and services in the pharmaceutical, For further information visit: medical technology and medical www.lifesciences.ukti.gov.uk www.onenucleus.com
Spring 2015 17
Member News
Controlling Deadly Inflammation in Critical Care complications of surgery, and many others, the body often produces vast excesses of cytokines as immune system messengers. If left unopposed, this ‘cytokine storm’ can cause massive uncontrolled inflammation, leading to the failure of vital organs. Multiple organ failure is the cause of nearly half of all deaths in the ICU, with no effective therapies to either prevent or treat it.
back to the body. It is approved in all 28 countries in the EU, with approximately 5,500 human treatments safely administered. CytoSorb has garnered the support of more than 300 key opinion leaders, with more than 50 investigator-initiated studies being planned or enrolling (predominantly in Germany, Austria, the U.K., and India), as well as more than $7M in recent US Department of Defense funding. CytoSorbents CytoSorb is a unique therapy has partnered with Fresenius capable of removing a broad range Medical Care - the world’s largest of cytokines, toxins, and other dialysis company, Biocon Ltd -Asia’s inflammatory mediators from blood, dominant biotechnology company, CytoSorbents Corporation with the goal of reducing the ‘fueland a global leading cardiac surgery (CytoSorbents), a US publiclyto-the-fire’ of inflammation. It company to help bring CytoSorb to traded critical care immunotherapy utilises highly biocompatible porous physicians around the world. company, is commercialising its polymer beads, each roughly the CytoSorb extracorporeal cytokine size of a grain of salt, which act For more information visit: adsorber in the EU and in many like tiny sponges to reduce these www.cytosorbents.com other countries worldwide to control inflammatory mediators from blood. deadly inflammation in critical care CytoSorb is used with standard and cardiac surgery. During lifehemodialysis machines found in threatening illnesses commonly most hospitals, where blood is seen in the intensive care unit repeatedly pumped outside of the (ICU), such as sepsis and infection, body, purified through the CytoSorb trauma, burn injury, lung injury, cartridge, and then recirculated
From Cambridge to Lausanne via One Nucleus’ Conference Genesis Innovation Forum is a nonprofit researcher-led initiative that connects professionals from academia, industry and policy. Founded in Cambridge in 2012, the network now boasts 12 branches globally, the latest being in Switzerland.
and his team to refine the kickoff event, craft key messages, coach in dealing with the media, and secure extensive coverage in the Swiss media. The event on 10 March at Ecole Polytechnique Federale Lausanne was attended by nearly 400, drawn by nine top-class speakers addressing policy, finance Genesis 2014 was one of the and the culture for successful catalysts for the successful launch of innovation and entrepreneurship. the new branch in Lausanne, when Marek Tyler, CEO, Innovation Forum Lausanne is at the centre of a asked Nick Miles of swiss-based PR thriving eco-system, close to world and strategic communications firm, leading universities and research Cabinet Privé de Conseils, to give a hospitals, successful companies in helping hand. The agency supported medtech, biopharmaceuticals and Lausanne Innovation Forum’s high-tech engineering, booming President, Manuel Fankhauser innovation parks and access to
sources of finance. It is the perfect location for Innovation Forum to be a successful catalyst for innovation in life sciences. For further information visit: www.inno-forum.org
One Nucleus has a formal collaboration with Innovation Forum. www.onenucleus.com
18 Member News
Spring 2015
Innovate UK Awards £8.2 Million to Advance New Regenerative Medicines and Cell Therapies
The Regenerative Medicine and Cell Therapy Programme was established in 2009 and has so far committed over £36m of funding to allow UK companies and their collaborators to undertake innovative projects. This funding has enabled treatments to go into clinical trials for the very first time in areas such as eye disease, wound healing, cartilage repair and immunotherapy. Many companies that have received support from Innovate UK have used this to leverage further, private financial investment. Recently Innovate UK announced the results of its 8th themed
competition in this area. In ‘Advancing Regenerative Medicines and Cell Therapies’ it was looking to support companies working on the preclinical testing, clinical development and manufacture of regenerative medicines and cell therapies, and those developing associated underpinning tools and technologies. In total, £8.2m was committed to support six projects, in areas as diverse as cancer immunotherapy, novel cord blood stem cell manufacturing, and development of new bioreactor technology. The complete list of winning projects is as follows: MultiStem for the treatment of acute respiratory distress syndrome • Athersys (Lead Partner) • Cell Therapy Catapult CAR therapy for multiple myeloma • Autolus
Kathy MacKay, Lead Technologist - Regenerative Medicine
Cell bandage for repair of torn meniscus – development of an improved product and a manufacturing process suitable for its effective commercialisation • Azellon (Lead Partner) • University of Liverpool
Ex vivo expansion of cord blood and bone marrow stem cells • Plasticell (Lead Partner) • Oxford University • Cell Therapy Catapult Novel platform technology for scaled down process development and optimisation of regenerative medicines • The Automation Partnership (Lead Partner) • Cell Therapy Catapult More information on these projects can be found on online here: www.bit.ly/1uQ25Bw
• NHS Blood and Transplant Further information on Innovate UK can be found: • Cell Therapy Catapult www.gov.uk/government/ Development, clinical validation organisations/innovate-uk and manufacturing scale up of FibroFix Meniscus: A mechanically advanced, tissue regenerative, meniscal cartilage repair implant • Orthox
www.onenucleus.com
Mike Sullivan, Lead Technologist Regenerative Medicine
Innovate UK, formerly known as the Technology Strategy Board, is the UK’s innovation agency. It guides, mentors and funds high growth companies, accelerating economic growth and helping companies to bring new products and services to market faster. Innovate UK focuses its activities on areas where the UK has strong capability and where it can make the biggest difference. One such area is regenerative medicine and cell therapy.
Spring 2015 19
Member News
Metrion Biosciences, a Specialist Ion Channel Screening Business Marc Rogers, VP Research at Metrion Biosciences
In May, Xention, the Cambridgebased biopharmaceutical company specialising in the development of new drugs for atrial fibrillation, announced the launch of Metrion Biosciences, a contract screening business focused on providing comprehensive and high quality ion channel services to the pharma and biotech industry.
The Metrion Biosciences team, led by Dr Marc Rogers, VP Research, has extensive experience of ion channel research, having brought five new Xention ion channel drug candidates to the clinic, conducted multiple research collaborations with international pharma businesses, and completed several UK and European grant projects. Dr Rogers is assisted by experienced ion channel Principal Scientists Dr Kathy Sutton and Dr Rob Kirby.
Metrion Biosciences intends to launch a new panel of in vitro cardiac ion channel and human cardiomyocyte assays for better detection of cardiac safety risks in new drugs, and will work towards full accreditation of its panel under the FDA’s new Comprehensive In Vitro Proarrhythmia Assay initiative Metrion Biosciences will provide (CIPA). In addition, Metrion will customers with dedicated ion market its panel of neurological ion channel screening and assay channel assays for pharmaceutical development expertise to support companies to profile and de-risk enhanced cardiac safety assessment new drug candidates. and the progression of drug discovery projects.
‘We have identified an opportunity to commercialise Xention’s long standing specialist expertise in ion channel biology. Xention was one of the pioneers of automated patch clamp electrophysiology and our deep experience of this field has enabled the company to collaborate in ion channel research with a number of international pharmaceutical businesses while at the same time developing a portfolio of potential breakthrough drugs for the treatment of atrial fibrillation,’ commented Dr Keith McCullagh, Chairman of Xention. ‘Metrion Biosciences represents a new initiative to commercialise our specialist ion channel expertise on a fee-for-service basis which will be more convenient and accessible for our customers.’ For further information visit: www.metrionbiosciences.com
Creating the Right Conditions for Growth The Rt Hon Dr Vince Cable MP (seated right) with GCGP LEP Chairman, Mark Reeve, (seated left) signing LEP Growth Deal
Norfolk, West Suffolk, Uttlesford and North Hertfordshire, the LEP focuses on overcoming the key barriers to growth:
The Greater Cambridge Greater Peterborough Enterprise Partnership (GCGP LEP) is committed to driving forward economic growth, creating
new jobs for local people, and helping businesses to flourish. Covering Cambridgeshire, Peterborough, Rutland, West
Skills: The LEP understands that having appropriately skilled staff to meet the requirements of local businesses is a key criteria for the success of our local economy. This is why it is working with businesses, colleges, training providers, universities, and Government to ensure that the right training opportunities are available in the local area. It also works, via The Skills Service, with schools to raise the aspirations of young people and make them aware of the career (Continued on page 20) www.onenucleus.com
20 Member News
Spring 2015
paths available to them in the local area.
improvements around Peterborough, Initiative that provides funding to and many other schemes. support the Agri-Tech sector.
Infrastructure: To enable the area to flourish it needs the right infrastructure. The role of the LEP is to find ways to overcome infrastructure issues that are holding back economic growth. This is why it is the single biggest local contributor to the A14 upgrade scheme, investing up to £50 million into this vital route. The LEP has also secured funding for the Ely Southern Bypass, A428 dualling,
Funding: In addition to investment in infrastructure and skills, the LEP secures funding for projects of strategic importance. For example, in the last twelve months alone, it has secured over £110 million via its Growth Deal to support a range of initiatives across the area including the creation of the Cambridge Biomedical Innovation Centre near Addenbrookes and an extension to the Eastern Agri-Tech Growth
One Nucleus’s CEO, Harriet sits on the formal Industry Advisory Group to the LEP. You can find out more by visiting: www.gcgp.co.uk
SPARK 2014 - A Showcase of SBRI Healthcare Innovations George Freeman, Minister for Life Sciences
SBRI Healthcare recently hosted a brand new event, SPARK 2014 Innovation Expo, at the QEII Conference Centre, London. As part of the Genesis fringe, the event brought together more than 50 companies showcasing the latest innovations with leaders and experts from government, the NHS, academia and industry. The day offered the 300 plus attendees plenty of opportunity to see products developed with funding from SBRI Healthcare, to explore the scope for further innovation, and to establish NHS partnerships. The keynote presentation from George Freeman, Minister for Life Sciences and Ian Dodge, National Director Commissioning Strategy NHS England discussed the challenges and opportunities www.onenucleus.com
in bridging the gap between health and economic growth. Iain Grey, Chief Executive Innovate UK and Prof Tony Young, National Clinical Director NHS England, followed with an insight into the economic and clinical value of the SBRI Healthcare programme.
they’ve developed with SBRI Healthcare support and funding. Many are already benefiting patients and clinicians around the UK. We are also delighted that George Freeman and other senior leaders from NHS England and Innovate UK showed their support and continued commitment to the programme. We Throughout the day all 15 Academic are already developing our ideas for Health Science Networks (AHSNs) the next SPARK event planned for who lead the programme, were on Spring 2016.’ hand to support and advise on the application process and potential Iain Grey, Chief Executive of focus areas for future competitions. Innovate UK added: ‘The SBRI process enables any part of the Since 2009 SBRI Healthcare has public sector to engage with new launched at least one competition a suppliers for mutual benefit year, offering contracts to innovative stimulating economic growth. SBRI small companies to develop new Healthcare is a clear example of solutions to meet NHS challenges. this in action. It plays a pivotal Over 2000 companies have taken role in ensuring small, innovative part to date, with more than companies get the opportunity to 100 contracted companies now turn bright ideas into commercially developing a pipeline of products viable products. It benefits with a potential cost saving to the patients, the NHS, industry and UK NHS of over £1billion. plc.’ Summing up the day, Karen Livingstone, National Director SBRI Healthcare, said: ‘SPARK 2014 shows what can happen when the NHS, academia and businesses connect. It was great to see so many companies showing us the technologies and innovations
Visit www.sbrihealthcare.co.uk, or follow SBRI Healthcare on Twitter @sbrihealthcare
Spring 2015 21
Member News
UK Drug Discovery Excellence on Show: India Harriet on the CEO panel discussion at Bangalore India Bio
its infrastructure – the UK has the investment, expertise and experience to make that happen. UK trade with India is growing – from £11bn in 2009 to £16.4bn in 2013 despite the economic slowdown in both countries during that period. The UK receives more Indian investment than what India invests in the rest of the EU combined. In 2013 the UK attracted 74 new projects from India generating 4482 jobs.
The UKTI team at the UK Pavillion Bangalore India Bio with Harriet in her Business Ambassador role
UK companies to date in this sector have predominantly been interested in: Clinical research collaboration at an early As well as being CEO of One with a Healthcare UK mission which stage, tech transfer, reagents for Nucleus, I was delighted last year was exploring the potential for screening, molecular diagnostics, to be invited by the Prime Minister healthcare-specific deals between oncology research and delivery (a to be a UK Business Ambassador our two nations. leading segment of the industry – for this amazing sector. The role is the market is expected to grow at a relatively light-touch, and sees me The week was hugely exciting; our compounded rate of 6.5% to $240 presenting UK expertise around the delegation was fortunate to have million by 2018), diabetes detection UK and internationally. One of the exceptional access to leading Indian and management, packaging and ‘hard’ commitments I agreed to was companies, fantastic emerging ones design, lab equipment, high end to lead a mission of UK companies and key opinion leaders from the drug development eg: neurology, to an appropriate market. various vital parts of the system – aged care and assisted living including investors, political leaders, technologies. Discussions took place throughout and scientists. The week saw a 2014, both with Lord Kakkar range of CEO panel debates and (another Business Ambassador) and discussions, networking receptions, with the Government; I strongly workshops, company visits, and encouraged the concept of a drug presentations from UK and Indian discovery mission to India. Such companies. With a suitably high a mission would provide an ideal profile at Bangalore BIO we saw opportunity to build on the two the UK Pavilion opened by Dr Kiran previous high level, but more Mazumdar-Shaw, CEO of Biocon, general, visits of the Prime Minister the largest biotech in India, and and major UK companies, and the Chief Executive of UK Trade & really get to the heart of what Investment, Dominic Jermey. the opportunities are for win-win collaborations between the UK and The following are some of my India in life sciences and healthcare. learnings from a hugely informative and inspiring trip: The mission took place in February – coinciding intentionally with the UK/India relations: No country largest event of its kind in India in the G20 invests more in India – Bangalore BIO. We had twenty than the UK. India is looking for organisations take part from the UK capital and the City of London is and as part of the plan, when we the worlds’ leading financial centre. moved on to Mumbai, we connected India is focused on modernising (Continued on page 22)
www.onenucleus.com
22 One Nucleus News
Spring 2015
Taslimarif Saiyed and Harriet at the panel debate
competition and government price controls.
The key themes for opportunities seem to be in: Healthy ageing, medtech (a 15% increase is forecast in the coming years), Bio IT/mobile health and bioinformatics, PPP, personalised medicine/regenerative medicine, health for the poor and investment in infrastructure. Great examples of UK success already: Include GSK, AstraZeneca and many multinational companies having agreements with Indian pharma. Horizon Discovery recently started their Bangalore office,
GE Healthcare has a physical presence in India working with a range of companies and hospitals, The Wellcome Trust has a formal relationship with the Indian Department of Biotechnology to fund R & D in affordable healthcare and the MHRA is working closely with Indian regulators for better training of regulators and improved overall systems and better exchange of information.
The latest state of play: There was broad positivity particularly from our Indian contacts on the new Government and the work of Prime Minister Modi. One senior businessman explained that he is running the country ‘like a company, with a strong commercial focus’. The Government has made no secret of its focus on IP and Innovation. There are currently over 350 biotechnology companies in India and that part of the sector is growing at 22% CAGR according to the recent EY report. Biotech revenues are currently at $4.5bn and there is a formally declared target of $100bn by 2025! Here I have profiled some of the UK and Indian organisations involved in the visit. I hope it gives you a flavour of the opportunities and expertise. I am particularly proud of the agreement that C-CAMP and One Nucleus have signed following the visit. Do read more about this from Taslim, the CEO of C-CAMP below and on page 23.
The Key Challenges for India include:
If you would like more information about the India market, please contact me: Regulation, Intellectual Property, PPP models, a relatively fragmented harriet@onenucleus.com eco-system with severe price
C-CAMP: Centre for Cellular and Molecular Platforms The Centre for Cellular and Molecular Platforms (C-CAMP) is a Department of Biotechnology (DBT, Government of India) initiative and a member of the Bangalore Bio-Cluster (which includes NCBS and inStem). C-CAMP was established with the aim of enabling cutting-edge bioscience research and entrepreneurship, by firstly making available state-of-the-art technologies and providing training on these technologies to academia and industry and secondly building a thriving ecosystem to stimulate www.onenucleus.com
innovation and promote bio-tech entrepreneurship in India. As a part C-CAMP’s mandate of promoting entrepreneurship and innovation, C-CAMP has created and fostered an entrepreneurfriendly culture in and around academic environment through its various activities which spans facilitating early stage discoveries made in the lab to very early stage ideas, to proof-of concept stage and validation studies for commercialisation.
C-CAMP has partnered with BIRAC, DBT to help with the Biotechnology Ignition Grant (BIG) scheme grant that funds start-up companies and individual scientific entrepreneurs to establish proof-of-concept and transform these innovative ideas into viable competitive products and enterprises. Through the BIG Entrepreneur Mentorship program, C-CAMP not only funds, but also nurtures these start-ups with scientific and business mentorship. C-CAMP’s involvement in the BIG scheme, has further expanded (Continued on page 23)
Spring 2015 23
One Nucleus News Taslimarif C-CAMP, Harriet and John Lownds UKTI
C-CAMP’s entrepreneurial activities to providing some of these start-ups access to a functional laboratory along with high-end technology platforms, through Bioincubation. For a biotech start-up, along with seed funding, access to such ready to use scientific infrastructure in a nurturing academic environment gives these young entrepreneurs
In addition, C-CAMP has been working with around 200 organisations, both academic and industry, through its technology platforms and entrepreneurship efforts. C-CAMP has also started the Early Translation Accelerator program which focuses on making early stage discoveries made in the lab more industry ready and takes them closer to the market through a possible license or spin-off. the kick start they need to propel them towards market and commercialisation.
For further information visit: www.ccamp.res.in
Today C-CAMP has funded (via BIRAC) and is mentoring around 45 life science start-ups/spin-offs, of which ten are incubating at C-CAMP, leveraging the technology platforms and scientific expertise on campus.
Regulatory Compliance in India - Myths and Facts Under Narendra Modi, the new Government’s maiden budget of 2015-16 has slashed corporate taxes, making India a highly lucrative investment destination. A lot of foreign participation is expected now, particularly in the healthcare sector. However, a spate of incidents in the last year has highlighted the lack of strict regulation in the sector, particularly with regard to quality control, intellectual property rights and regulatory compliance. With a bid to curb this menace and ensure a level playing field, the government now plans to table the 2013 Bill on Medical Devices, which proposes to make registration compulsory for every medical device being launched in India. CDSCO (the Indian FDA equivalent) rules stipulate that every foreign company launching its medical products in India must have these registered through an authorised Indian Agent, who would be legally responsible to CDSCO for all regulatory compliance
and subsequent product liability. But often, unsuspecting foreign companies are taken in by unscrupulous distributors who promise to ensure sales volumes without focusing on the regulatory compliance, to avoid product liability at a later stage. What these distributors invariably do not reveal is the fine print regarding appointing of authorised Indian agent in the Registration Certificate for a period of three years and the requirement of a NOC (No Objection Certificate) to change the agent. Some distributors even go to the extent of importing the products without registration to reduce expenditure and increase margins. This is a potentially risky situation and can pose serious legal complications for the manufacturer, if caught. While the distributor would merely shelve the product and may start selling alternatives manufactured by competitors, the parent UK company would get blacklisted and be disqualified to further market or register its
products in India. European SMEs can ill-afford losses attributable to a bad choice of distributors. Registration in India is now a much easier process and takes anywhere between six to nine months, though under a good agent this can be achieved in as little as four months. SMEs who cannot afford the fees charged by global regulatory agents can now partner with equally capable Indian consultants to undertake regulatory compliance. A good choice of partner will ensure continued business and sustained profits. Admirus India is a one-stop business solutions provider with specialty in the market regulatory space and provides independent incountry representation services. Visit www.admirus.in for more information.
www.onenucleus.com
24 One Nucleus News
Spring 2015
Wig-O-Mania - Determined to Make a Difference Wig-O-Mania is a UK brand that manufactures and promotes a complete range of hair pieces wigs and hair extensions - catering to both the fashion industry and necessity wearers in various parts of the world. Wig-O-Mania is the first UK hairpiece brand to have a base in India thanks to the support and guidance from UKTI (UK Trade & Investment) teams in both London and India. The company participates in various missions organised by UKTI in the Middle East and India to create awareness about the need and availability of hair pieces for people suffering from
hair loss due to medical reasons, for to offer discounts on products and support to affected groups and example following chemotherapy. individuals. Awareness is still in a relatively basic stage in the Middle East, India and Pakistan where the entire therapeutic focus is on the physical aspect of treatment, and neglects the mental trauma and psychological impact hair loss can have on a patient. Wig-OMania is determined to make a difference, not only in its efforts to participate in conferences, seminars and exhibitions to talk about this agenda, but also its willingness to partner with NGOs and hospitals
Hasnain Mohamedali, CEO of WigO-Mania commented: ‘UKTI and its events have always played an important role in supporting our cause. We look forward to attending similar events in the future to raise awareness and to network with likeminded people and businesses.’ For further information visit: www.wigomania.com
Medibox Technologies India Medibox Technologies (Medibox) is a location based Healthcare Information Management Platform for digitally connected devices in India. The company has developed a mobile application that predicts the availability of medicines, medical devices and medical services, and then matches this information to patient needs. The digital platform lets users know the nearest provider that can meet individual healthcare and medicine requirements as well as using analytics to, for example, regulate inventory and provide insights on non-availability of any service or product.
that are not yet available in India. Despite there being a market, it is not always clear how and where these product and services can be sourced. Conversely, there are many international companies that wish to tap in to the Indian healthcare market but are uncertain where to start. Using data gathered through its network of channels including distributors, pharmacies, patients, Medibox can provide information to international organisations about the healthcare requirements in India.
The Medibox concept was selected for presentation at HealthTech This on-demand SaaS (Software as Innovations 2015, initiated by a Service) platform is cloud-based the Department of Electronics and uses collaborative intelligence and IT, an Indian Government to provide real-time visibility and initiative in collaboration with accurate information on healthcare, NHSRC (National Health Mission) medicines and medical services. and the Indian Council of Medical This end-to-end information Research. Following a presentation aggregator provides insights, in January this year, Medibox is root cause analytics and response now in discussion with the relevant management tools. It is free for departments to implement the patients. Pharma and healthcare platform on a national level. stakeholders use its enterprise version. The founders of Medibox are Bhavik There are many global healthcare Kumar and Kapil Kanbarkar who products and unique solutions met as classmates at MIT Sloan www.onenucleus.com
School of Management, Boston where they completed their senior executive management programs in December 2014. Bhavik has 13 years of work experience, previously as CEO of a pharma company and is an expert in pharma and healthcare distribution, marketing and sales with global experience. Kapil brings over 15 years of software product development and management experience in the areas of big data analytics, cloud and enterprise software development. Bhavik Kumar, co-founder of Medibox commented: ‘Kapil’s and my common interest in solving some of the healthcare challenges in India brought us together to start Medibox. We are delighted that Medibox has been recognised by key global organisations and selected by Google for its Start-up Launch, Microsoft for Bizspark and IBM on its Partner World program.’ For further information visit: www.medibox.in
Spring 2015 25
One Nucleus News
One Nucleus In Action: United We Stand
Formally launched in October 2014, the Founder Members (One Nucleus, BIA, Bionow and BioPartner UK) have now welcomed a fifth member to our strategic partnership – MediWales. Between us, these five organisations have over 1,100 life science and healthcare members across the UK and further afield. So what have we been up to since we launched both ULS and our Life Sciences Manifesto 2015 – 2020 last year? The most important element of our collaboration is bringing benefits to our members and joining together the UK sector. Benefits to members include:
Geoff Davison, CEO, Bionow and Harriet Fear at the Bionow Awards Dinner 2014
As many of our readers will know, One Nucleus is proud to be a Founder Member of United Life Sciences (ULS). I thought it timely to bring you up to date with how this exciting and practical collaboration is developing and importantly, what it means for our members.
policy recommendations to Government and the other political parties, based on our members feedback at a set of roadshows – one clear voice into Government, which is absolutely vital if a difference is to be made. • Working together to provide a combined approach at large international events. For example, at BIO 2014 we arranged a joint webinar and promotional package showcasing activities taking place at the event. The same is planned for this year and ULS representatives will be on hand to support our collective membership; Tony Jones from One Nucleus; Steve Bates and Karen Chandler-Smith from the BIA; and Debbie Laubach from MediWales.
• Discounts on each other’s top 3 events which include Genesis; the BIA BioScience Forum; Bionow’s BioCap; One Nucleus’s ON Helix Translational Research Conference; MediWales’ UK Healthtech Conference; Bionow’s Annual Awards Dinner and • BioPartner UK offers the highest the BIA’s ’s annual BioProcess Conference. • Joint hosting of events around the UK to bring together our members more often than may otherwise be the case, at the same time as reducing duplication of effort by membership organisations • Continued support for BIA as the ‘voice of the UK sector’ – the Life Sciences Manifesto pinpointed the key issues for the sector and made
rate of discounts available to ULS company members (and provides representation on UK stands) for ULS organisations at a range of specific events including BioEurope and BioPharm America. • Influencing UK Trade & Investment strategy – this year has seen us send a combined Industry response to UKTI Life Science Organisation’s draft strategy. This was compiled on behalf of ULS and importantly also ABHI, BIVDA and GAMBICA who were keen to add to the strength of our response. As an ongoing piece of work, we are hopeful that UKTI will take the joint Industry view into account and adapt strategy accordingly.
Representing over 1,100 Life Science and Healthcare cvompanies in the UK
For more information, please visit: www.onenucleus.com/united-life-sciences
www.onenucleus.com
26 One Nucleus News
Spring 2015
The One Nucleus Life Science Leadership Series Our Life Science Leadership Series with recognition that locating seminars was held in The Shard, of events are themed by technology in premier regions such as in Spring, kindly hosted by Mathys focus, therapeutic area or industry Cambridge comes with a higher & Squire, where the subject challenge. Current approaches, price tag in terms of space and matter was Genomics in R&D and challenges and potential solutions staff costs. Partnering. The seminar included are presented to and debated with presentations from sponsors a peer group of up to 100 attendees • Enhanced communication: Covance, Farr Institute, Eagle active in the area. Collective This was a plea to a wider Genomics and Illumina that set sharing and discussion of the major group than investors alone, but out how developments in NGS issues ensure the participants included aspects such as better (next-generation sequencing), leave better informed and better communication from companies, bioinformatics and data analytics equipped to develop strategies to investors and support agencies are enabling exciting progress enhance their own business’ global to non-specialist audiences in patient stratification and competitiveness. about the inherent benefits and personalised medicine to be made, value creation opportunities of whilst innovative collaborative In late September 2014 attendees the life sciences sector. Also, structures between leading gathered at Chesterford Research better engagement with the stakeholders are enabling the Park to discuss Investment financial and general press to assembly of a critical mass of Strategies in Life Sciences, from ensure due coverage for the data. This led the way nicely into the company perspective. This sector’s successes. presentations from Ipsen and was a follow-on to the equivalent Amgen on their current partnering event the previous year looking at the same issue from the investors ‘The Life Science Leadership Series of events perspective. The presenting are themed by technology focus, therapeutic companies included those area or industry challenge.’ developing novel therapeutics and those commercialising innovative platform technologies. In a final session, two public companies, Early 2015 saw our next leadership requirements and strategies, before Abzena and Cyprotex, described event take place at the Babraham Vivia Biotech closed the meeting their need to court public market Research Campus where the with a presentation of their leading investors, and the challenges topic was Immunotherapies edge ExviTech platform technology, surrounding this activity. The full in Cancer. MedImmune, Merck which allows new therapeutic agenda and presenting company Serono and PharmaVentures set agents to be assessed in ex vivo, details can be viewed via out why interest was so high in but native, bone marrow samples. www.onenucleus.com/onenucleusthe sector, what the commercial events?id=771 opportunities may be and what As this issue goes to press, combination therapies, including ‘Anti-microbial Resistance’ The speakers were asked to immunotherapies, may look like and ‘Strategies and Funding conclude their presentations with in the future. These strategic of Clinical Trials’ events are a key request to investors in the presentations were then followed by scheduled for 20 May and 24 sector. Whilst there was debate a showcase of emerging innovative September, respectively, both over the correct targets for these technologies in the drug delivery at Chesterford Research Park, messages, their collective wish list and CAR-T (Chimeric Antigen Cambridge. included: Receptor T-cell) fields and insights into solutions for common problems To register please visit: • Recognition of the importance in the manufacturing, preclinical www.onenucleus.com/onenucleusof non-dilutive funding to early testing and regulatory arenas. events stage actors, the Biomedical Catalyst Fund having brought A full summary of the meeting can true benefit to companies and be viewed here with available slides their investors alike. accessed via www.onenucleus.com/ onenucleus-events?id=849 • Investment in the key requirements for growth, The latest of the leadership Director of Business Development www.onenucleus.com
Spring 2015 27
One Nucleus News
One Nucleus at BIO 2015 As always, we can expect the annual BIO Convention to be a mega hub of partnering, conference sessions, exhibition and receptions. This year it descends on Philadelphia from 1519 June and One Nucleus will again be facilitating its members in getting the maximum benefit possible out of attending. From previous years, many will know that we do this by creating additional networking, meeting and cost saving activities to year’s dinner will take place on the complement rather than complicate 100 year old ship, The Moshulu, planned activities. with a cocktail reception followed by dinner. Ahead of the big event, and if you are yet to reserve your flight and Registration for the One Nucleus Bio hotel, remember to take advantage Executive Dinner is now open at: of the services of Flight Centre www.onenucleus.com/onenucleusBusiness Travel (FCBT). As a events?id=887 Support Supplier to One Nucleus members, FCBT has exclusively One Nucleus - Stockholm negotiated significant discounts Uppsala Breakfast and our plan on air fare and hotel rates in for 2016 Philadelphia. In addition, One Nucleus will be liaising with other Date: Monday 15 June stakeholders such as UK Trade Time: 07.30 – 09.00 and Investment, MedCity and the London Mayor’s Office in order to Previous years have seen One keep you updated on activities One Nucleus hold breakfast panel Nucleus members can participate in debates with a UK, European whilst in Philadelphia. and US perspective, on topics Check out our plans at: www.onenucleus.com/onenucleusevents?id=827
One Nucleus Bio Executive Dinner Date: Sunday 14 June Time: 18.00 -21.00
such as ‘Patient Registries’, ‘Open Innovation’ and ‘Building the Right Environment’. Chaired by the illustrious characters Mike Ward, Chief Content Officer Scrip Intelligence and Datamonitor, and John Carroll, Editor, FierceBiotech, the sessions have attracted over 75 attendees engaged in understanding the dynamics of our sector.
is required from other stakeholder groups in order to address the issue(s). Our specific challenge for this series will be in the field of Companion Diagnostic development with the stakeholder groups of Pharma/ Biotech, Dx Companies and healthcare providers/payers. The series of discussions will culminate at BIO 2016 in a high level round table where each wish list will be assessed collectively to deliver a plan of action on a selected companion diagnostic project. That selected project plan will be made available for financing and strategy testing with interim outputs of discussion drafted as white papers to ensure wider community engagement and contribution. For more details please contact: tony@onenucleus.com
BIO New Jersey exclusive offer As a result of our relationship with Choose New Jersey, One Nucleus has reserved a small number of places on some BIONJ site visits to key locations as follows: Tour 1 - Research Rutgers: Behind the Scenes at The State University of New Jersey - Sunday 14 June (09.00 - 16.00) Go behind the scenes at Rutgers University and learn how collaboration leads to discovery. Tour the renowned RUCDR Infinite Biologics, the world's largest university-based biorepository, and the Rutgers Continuous Pharmaceutical Advanced Manufacturing Laboratory, which is working with more than 30 pharmaceutical companies.
2015 will see a change to the Each year One Nucleus collaborates traditional format as we seek to with our Partners, BIOCOM, BayBio evolve these breakfast sessions and MassBio as well as other invited to deliver even more tangible organisation, to assemble up to outcomes. The event at BIO 2015 100 biopharma executives from a will be the first of a series of round variety of geographies to participate table sessions over the next 12 in peer-to-peer learning over dinner months to coincide with global before the formal BIO Business events, such as BIO and BioEurope Engage in conversations with Forum commences. (Spring and Autumn). Each round Rutgers researchers and faculty table will bring together a single over lunch and learn about Hosted by our Corporate Sponsor, stakeholder group to discuss a Johnson & Johnson Innovation, this common challenge and debate what (Continued on page 28)
www.onenucleus.com
28 One Nucleus News
Spring 2015
opportunities for collaboration at one of the nation's top research universities.
in biobanking, induced pluripotent stem cells, and personalized medicine. Learn about the Institute's research service offerings and tour the world's most diverse biobank.
Tour 2 - The Cave, Coriell and Camden - Monday 15 June (09.00 12.30)
Visit the website to register for the tours: www.choosenj.com/ BIO2015NJTOURS
Home to cutting-edge research, South Jersey Technology Park at Rowan University houses 16 sponsored research labs. Tour the labs and the showpiece of the Technology Park, the CAVE, a virtual reality (VR) environment in which teams conduct detailed, and costeffective research.
To secure your place please contact Jessica Paolini on Jpaolini@choosenj.com mentioning One Nucleus in your email.
Then take a short ride to Camden to visit Coriell Institute, a world leader Director of Business Development
Possible Presidential Candidate Meets One Nucleus Members In February we were honoured to host a Roundtable Breakfast with Chris Christie, the Governor of New Jersey. As many of you will know, One Nucleus has a very strong international focus and the approach from the Governor’s team was welcomed warmly by One Nucleus members. The meeting was a key opportunity for us to hear from the Governor about the life science and
healthcare sector in the pharma heartland of New Jersey – and timely given that BIO this year will be just down the road in Philadelphia. The meeting saw a lively Q & A session with the Governor and his team, (including the President of Rutgers University), being quizzed on all manner of topics – from technology transfer to Lilly asking him what his style of Governance is!
With the rumours rife that Governor Christie may throw his hat into the ring for the Republican candidacy for the Presidency, One Nucleus Chair Jon Green asked him to remember us if he gets there...
Harriet and our Chair Jon Green welcome the Governor of New Jersey
The meeting was of course not just about that moment. As ever, One Nucleus has thought about what next. We are in close touch with the Choose New Jersey (economic development) team and are delighted that they are to be involved in our plans for BIO – organising tours for One Nucleus members. Do contact Tony tony@onenucleus. com if you are going to BIO and would like to be involved. For more information about New Jersey, you can click on the link to download the brochure: www.onenucleus.com/download. aspx?id=1569
www.onenucleus.com
Spring 2015 29
One Nucleus News
ON Helix 2015 - De-risking Research, Partnerships and Funding 14 July 2015 Cambridge, UK
Our third ON Helix Conference will be taking place this year on 14 July at the Wellcome Trust Conference Centre, Hinxton, Cambridge. Being held in heart of the world renowned Cambridge Cluster, this unique Translational Research Conference attracts the best from all areas of the life science industry, bringing scientists from some of the top universities in the UK together with talented individuals and organisations from the life science and healthcare sector. This year, ON Helix will be sponsored by AstraZeneca, MedImmune, Horizon Discovery and Abcam, and supported by the Wellcome Trust Genome Campus, EMBL-EBI and Chesterford Research Park highlighting the importance of this event in the sector and specifically, translational medicine. The one day event aims to inform delegates of how to turn early stage inventions and ideas into innovative healthcare treatments. It will present the business environment, funding, scientific and clinical research excellence of the UK, forming a unique knowledge-sharing environment between academia and business.
Translating UK scientific excellence into global therapeutic strategies
The conference will be opened by Bahija Jallal, Executive Vice President of AstraZeneca and Head of MedImmune. In this role, Bahija is perfectly placed to share the company’s strategy, insights and approaches to the critical importance of translational research. With the move of AstraZeneca’s global headquarters to Cambridge well under way, and more than 500 scientists already here, Bahija will expand on the work MedImmune and AstraZeneca are doing to encourage and enhance the translational research environment in the UK and globally.
The three main themes of this conference are: • De-risking Research: Collaborative Models • De-risking Partnerships: Sharing Data in Collaboration • De-risking Funding: Investing in Early Stages of Development
Newly renovated exhibition space at the Wellcome Trust Conference Centre
Interactive case studies will be a feature at ON Helix this year, where each speaker will present their story, their approaches to translational research and what they believe leads to success and Our other Keynote speakers include failure in these areas. There will Nicolas Sireau, Chairman of the be plenty of time built in to each AKU Society, a charity that works session for questions and debate in partnership with the Royal from the floor. Our speakers Liverpool University Hospital to find include Professor Sir Philip Cohen, a cure for AKU, an orphan disease University of Dundee, Dr Darrin affecting Nicks two sons. And Farid Disley, Horizon Discovery, Dr Stuart Bidgoli, Associate Director of Market McElroy, European Screening Centre Access for Merck Sharp & Dohme, Newhouse, Dr Robert Tansley, who will talk about what the future Cambridge Innovation Capital and could hold for patients if healthcare Professor Steve Jackson, MISSION systems embrace digital health, Therapeutics and University of data and health informatics. We will Cambridge. also be welcoming the Minster for Life Sciences, George Freeman. On 13 July, to open ON Helix 2015, One Nucleus will be holding a Welcome Reception which will include our BioNewsRound Awards and a panel discussion at EMBL-EBI. For more information about ON Helix, please visit www.onhelix.com or contact nadia@onenucleus.com
www.onenucleus.com
30 One Nucleus News
Spring 2015
Genesis 2014 - Key Highlights of the Event: A Delegates Perspective
Stepping through the main door into the Queen Elizabeth II Centre, you instantly feel a warm welcome that adds to the anticipation of an event with a huge gathering of over 700 delegates representing 400 life science and healthcare organisations from 25 countries. The arena at Genesis is always full of presentations, debates, and exhibitions. One of the new initiatives in 2014 was the One Nucleus Source Lounge, sponsored by MedCity. The lounge had a dedicated space within the main exhibition hall, with four hubs for finance, innovation, international and R&D, as well as space for the Source Advice Group. The aim of the area was to maximise the networking opportunities of attendees in specific areas.
Mike Ward, Chief Content Officer, Datamonitor Healthcare and Scrip Intelligence at Informa
www.onenucleus.com
Kit Malthouse, Deputy Mayor of London for Business and Enterprise
In early December, as for the last 14 years, One Nucleus hosted one of the most renowned international networking events of the year. The annual Genesis conference provides a unique and interactive environment for those who aspire to be updated on trends in life sciences and healthcare, to explore and challenge their own and others’ ideas, and to generate new business dealings and partnerships.
Harriet kicked off the main event by encouraging the life science and healthcare companies, institutions and governments to connect with each other to bring about strategic and collaborative initiatives that would create tangible benefits for members and nonmembers. Her ultimate aim is to help maximise the local and global competitiveness of UK science and technology-based organisations. On this note, Harriet pointed out the significance of the formation of United Life Sciences. Four leading membership organisations: the BioIndustry Association; Bionow; BioPartner; and One Nucleus (and since February 2015 MediWales too), share the same spirit and philosophy and are working
together and liaising with the UK Government and policymakers to further promote and encourage an environment that will sustain growth in the sector across the UK. The key highlights drawn from the plenary session were that healthcare systems are focusing on delivering better outcomes and tackling the challenges in personalised and stratified medicine to deliver valuebased healthcare. Adrian Towse, Director at the Office of Health Economics, set the scene well. The cost of healthcare provision is rising due to more complex and expensive therapies on offer and an ageing population, changes in lifestyles and environment. Individual patient outcomes are not improving at a rate that matches the increasing healthcare spend. Ken Sutherland, Company President of Toshiba Medical Visualisation Systems, asked the question, ‘can the application of technological innovation and computer science reduce the gap?’ He outlined that data analytics and individual-centric data would empower the development of technologies to enable the delivery of an information-driven healthcare framework, helping healthcare professionals to deliver costeffective outcomes and efficiently manage time and resources. The (Continued on page 31)
One Nucleus News session was rounded off by Rowan Gardner, Chairman of BioLauncher, using her own experience to present how well the NHS serves patients already and how technology adoption will enhance this further.
Mike Ward led the One Nucleus plenary debate during which the panellists discussed the question: what kind of life science companies should we be building? The key points emerging from the debate Mike Ward, Chief Content Officer, were that there is a need for more Datamonitor Healthcare and Scrip investment initiatives which would Intelligence at Informa delivered then lead to greater investment a fascinating presentation on into the sector. For example tax 2014 Winners and Losers in the incentives for early funding. There biotechnology and pharmaceutical was also unanimous agreement that industries drawing upon the one of the key factors to success is analytics and market performance people. Indeed a company’s best of major market players. One of the asset is its human capital, and to winners of the year in his view was thrive companies must either create AstraZeneca’s CEO, Pascal Soriot. or develop a management team that will lead them to success. The parallel sessions enabled participants to choose talks that Kit Malthouse, Deputy Mayor of best fitted their interests. The focus London for Business and Enterprise of these sessions ranged from delivered the closing Plenary Speech industry deal case studies, through with a clear message that he wishes partnering with big pharma, and to promote and establish London how emerging technologies enable and the UK as a world leader in R&D efficiency to the changing life-sciences innovation. He pointed regulatory environment in med out that the greatest challenge tech. In the Imaging in Drug facing the sector is to create and Discovery and Development session encourage a culture of investment led by Kevin Cox, Imanova’s CEO, and collaboration. MedCity was the key take-home message was founded in part to address this that imaging (ie. PET and MRI) can issue. be used as a tool to optimise and reduce risks in the research and As the event drew to a close, development of drugs. participants made their way to
London’s premier Life Science & Healthcare networking conference
Spring 2015 31 the main exhibition hall for a glass of mulled wine, mince pies, and a chance to continue their conversations until the doors of the centre closed. Genesis has created such a buzz over the years that the One Nucleus team are regularly inundated with requests to be involved in or promote events around Genesis. For 2014 with this in mind they created the ‘Genesis Fringe’ - With the main Genesis day acting as the centrepiece, the Genesis Fringe provided delegates and a further 400 attendees with a chance to engage in a range of targeted satellite collaboration events over the surrounding days. The word is that they are planning the same for 2015 so watch this space! Congratulations to all members of the One Nucleus team, the speakers, collaborators and attendees for creating such a fantastic conference. Roll on Genesis 2015! Contributed by: Maria-João Martins, Founder, Life Sciences Sharing Ideas (LSSI) Visit www.genesisconference.com for 2015’s programme.
Tweet with tags #ongc15
genesis 2015 10 December 2015 Queen Elizabeth II Conference Centre, Westminster, London, UK genesisconference.com
www.onenucleus.com
One Nucleus Dates for your Diary 2015 MAY 21
JUN 03
JUN 03
JUN 14
Immigration Breakfast Seminar Penningtons Manches, Cambridge
JUL 22
BioWednesday: Theme: Developing and Commercialising Cell-Based Platforms EIP, London
SEP 02
Innovation Day - Droplet Digital™ PCR Babraham Research Campus, Cambridge
SEP 16
Network Meeting Deloitte, Cambridge
SEP 24
Life Science Leadership Series ‘Strategies and Funding of Clinical Trials’ Chesterford Research Park, Cambridge
One Nucleus BIO Executive Dinner The Moshulu, Philadelphia, USA
JUN 30
Network Meeting Summer Social Granta Park, Cambridge
JUL 08
BioWednesday: Future Directions in Oncology LBIC, London
OCT 14
JUL 13
Welcome Reception and BioNewsRound Award EMBL-EBI, Cambridge
OCT 21
JUL 14
ON Helix Wellcome Trust Conference Centre, Hinxton Hall, Cambridge
NOV 11
JUL 15
JUL 21
M11 Med Tech Forum Harlow
Penningtons Manches’ Breakfast Cambridge
Amgen Day British Library, London
OCT 07
BioWednesday Olswang, London
BioWednesday: Life Science in Benelux Instinctif, London
Network Meeting Marks & Clerk, Cambridge
M11 Med Tech Forum Harlow
BioNewsRound Award Semi-final Queen Mary BioEnterprises, London
NOV 25
Network Meeting Stevenage Bioscience Catalyst
DEC 10
Genesis QEII, London
www.onenucleus.com/onenucleus-events
Translating UK scientific excellence into global therapeutic strategies
14 July 2015 Cambridge,UK
The Wellcome Trust Conference Centre, Hinxton, Cambridge • A unique UK Translational Research Conference • Keynote addresses by opinion leaders • An interactive case study based programme
• Practical insights on funding and collaborations in translational research projects • A networking platform for academia and businesses
Keynote Presentations The conference will be opened by Bahija Jallal, Executive Vice President of AstraZeneca and Head of MedImmune. She will be followed by Nicolas Sireau, Chairman of the AKU Society, a charity that works in partnership with the Royal Liverpool University Hospital to find a cure for AKU, an orphan disease affecting his two sons. And Farid Bidgoli, Associate Director of Market Access for Merck Sharp & Dohme, talking about what the future could hold for patients, if healthcare systems embrace digital health, data and health informatics.
Dr. Nicolas Sireau, Chairman of the AKU Society
Dr. Bahija Jallal, Executive Vice President of AstraZeneca and Head of MedImmune
Main Themes of the Conference De-risking Research: Collaborative Models De-risking Partnerships: Sharing Data in Collaboration De-risking Funding: Investing in Early Stages of Development We are proud to be the first external conference to be taking place at the transformed Wellcome Trust Conference Centre, Hinxton, Cambridge Follow us on Twitter @OneNucleus and use #onhelix15 Register at onhelix.com
Dr. Farid Bidgoli, Associate Director of Market Access for Merck Sharp & Dohme
34 One Nucleus News
Spring 2015
Our Corporate Patron, Corporate Sponsors and Partners Update A reflection of the platform One Nucleus creates for those seeking to play a central role in the development of the Life Sciences sector is the array of key organisations supporting us through sponsorship and insight as we collectively work to engage and inform the wider ecosystem.
MedImmune
Global Data
Amgen
Johnson & Johnson Innovation
Andrew Porter Limited
London Bioscience Innovation Centre
AstraZeneca
Nature Jobs
Babraham Bioscience Technologies
Norgine
It is important for One Nucleus that we select our supporters carefully such that they reflect the breadth of the Life Sciences innovation chain and needs of our membership base.
BioMed Realty
Penningtons Manches
BioRelliance
Pharma Training International
Charles Russell Speechlys
PharmaVentures
We are delighted to have MedImmune as our Corporate Patron, with Bahija Jallal preparing to be the opening speaker at this year’s ON Helix Conference.
Chesterford Research Park
PPD
Covance
Queen Mary BioEnterprises
Deloitte
SCRIP Intelligence
EBD Group
Stevenage Bioscience Catalyst
This adds to the vast variety of speakers and panellists who have presented over recent months at our leadership seminars and networking meetings, all sharing their insights. Our Corporate Sponsors include Taylor Wessing, Deloitte, Andrew
first sight media
Taylor Wessing
Global Regulatory Services
Wellcome Trust Sanger Institute
Porter Ltd, Chesterford Research Park and, most recently, Johnson & Johnson Innovation, all major companies, influencers and
employers in the Life Science and healthcare sector. The One Nucleus Partner Programme continues to expand, adding further stakeholders capable of providing market intelligence, strategic insight, R&D facilities, expert advice and out-sourcing options to all our members. For information on how to become a Sponsor or Partner please download the brochure www.onenucleus.com/ download.aspx?id=1554 and review our website www.onenucleus.com/ sponsorship Alternatively, contact Tony Jones to discuss further tony@onenucleus. com If you are a One Nucleus member and would like to receive the logo below, to include on your website, please contact: info@onenucleus. com Member of
Source R&D - Finding and Celebrating the Best Outsourcing Solutions The One Nucleus and Bionow inaugural edition of Source R&D, a directory showcasing organisations that provide expert advice and services to new medicine developers, was launched at Genesis 2014. It came about as a result of dialogue with One Nucleus and Bionow members who were keen to engage in providing a global shop window for the world class expertise and services offered by our respective members. In addition to product sales, the provision of services is a significant value driver of the biopharma sector in the UK, with much of the www.onenucleus.com
business originating from overseas. The true economic value, job creation and capacity however are often overlooked when promoting our strengths in this field, unlike the much celebrated counterparts in the Financial Services sector.
piece of work, with plans already underway to capitalise further on the first publication through updating and deepening of the data in order to: • Accurately reflect the strengths of One Nucleus and Bionow R&D service providers
Source R&D is a first step along the road to correcting this oversight and serves to counteract the lack • Generate the data to articulate of celebration of UK excellence to the economic value in terms date. The directory brings together of revenue, employment and editorial content discussing outpotential sourcing strategy, a showcase of exemplar providers and a listing • Dispel the myth that the UK of all members in the space. This does not do translational is not a stand-alone or ‘one-off’ research which is often quoted (Continued on page 35)
Spring 2015 35
One Nucleus News as a weakness when in reality a vast amount occurs, just under foreign sponsorship
- those who enable companies to a develop drug development strategy prior to either in-house or out-sourced delivery of the clinical trials.
Again in collaboration with Bionow, our sister publication, Source • Technology Services – those Clinical, is in development and businesses providing the aimed at illustrating our members’ associated technical services to collective expertise in value creation enable clinical development. in this important sector. This is an area again that is likely to • Professional Services – those advisers providing associated prove to have been under-estimated services to drug developing in terms of its economic impact clients. in the UK as the focus has been on reporting products rather than services as outputs from the sector. Our aim is for Source Clinical to cover four main categories of expertise: • Clinical CROs - those that undertake the trials. • Clinical Development Advisers
The common theme to Source R&D and Source Clinical is to maximise the benefits for all businesses of being part of a membership group and ecosystem by complementing the current opportunities offered.
New Training Courses confidentiality agreements, R&D contracts and manufacturing and process development to name a few. We are delighted to announce that One Nucleus is now a quality assured training provider for the Science Industry Partnership (SIP) New content has continued to be Small Business programme - a added to the training portfolio Government funded initiative. Your since October 2014 and we have welcomed a number of new soft skill company may be eligible for 50% reimbursement for the cost training providers to further enrich of some training courses. the training service. For example: 2015 has got off to a great start with 11 training courses taking place in the first quarter already. Places are already being booked for our Autumn dates.
We delivered two Introduction to Contracts training courses in conjunction with Marks & Clerk last year. Due to its success we will be running the course again in 2015, dates to be confirmed for October. The course is aimed at anyone involved in negotiating and managing contracts in a life sciences firm or university tech transfer office. This practical course covers the basic contract law issues for example, privity, warranties and indemnities, and competition law. Also included are the different types of contract for life science companies such as assignments,
As many members are already aware, we work in partnership with Pharmaceutical Training International (PTI), a global interactive training provider. Between the portfolios of One Nucleus and PTI, members can access discounts on over 80 tailored training courses covering the breadth of the life science industry, including; Agrochemicals, Animal Health, Biopharmaceuticals, Clinical Development, Fine Chemicals, Generics, Health & Safety, Manufacturing, Medical Devices, Regulatory Affairs, Research and Development, Softer Skills including
Providing ready access to the expertise and services present within our R&D and Clinical Development service providers, the Source publications enable companies to seek advice early in their planning cycle. Providing ready access to the expertise and services present within our R&D and Clinical Development service providers, the Source publications enable companies to seek advice early in their planning cycle. Provoking and solving high quality questions early, enables those undertaking translational research and product development to remain competitive in a constantly changing environment. View the online directory: www.issuu.com/one_nucleus/docs/ urce_r_d_directory
Director of Business Development Powerful, Presentations, Project Management, Negotiation and Communication. All of our courses can be adapted and tailored to meet your needs, and can be delivered cost effectively in-house so please contact training@onenucleus.com to find out more.
SEPT 3
The Safe Use and Management of Laboratory Gases
SEPT 14
Introduction to Drug Development - Scientific Professionals
SEPT 17
Introduction to Drug Development - Non-Scientific Professionals
SEPT 22
Introduction to Management (3 day course)
OCT 6
Leading Virtual Teams
OCT 12
Managing Change
NOV 2
Introduction to Lean and Six Sigma
www.onenucleus.com
36 One Nucleus News
Spring 2015
The One Nucleus Purchasing Scheme: Saving Our Members Over £4 million a Year In December 2014 the Purchasing Consortium tendered for the Preferred Supplier for Dry-Ice and Associated Services. We are pleased to announce that BOC has been awarded a 3 year contract which started on 2 January 2015.
In February the Purchasing Consortium tendered for the Preferred Supplier for Compressed Gases and Associated Services and Air Liquide were awarded a 3 year contract starting on 1 April 2015. ‘We are delighted to have won the
compressed gases tender and to be able to continue to support One Nucleus and its members. We have been involved with the sector for many years and look forward to continuing our relationship with the membership.’ Charles Dore, Contract Manager, Air Liquide.
Our Support Suppliers Our Support Suppliers continue to grow in number and offer discounts to ALL our members. For the full list please see the Purchasing pages on the One Nucleus website.
We can perform a cost-benefit Richard Dickinson on 01223 896453 analysis for Silver members thinking or richard@onenucleus.com of upgrading to Gold membership or new companies wishing to join Here are our newest suppliers: as Gold members. Please contact
Company
SSA
Contact
Phone
A4PBIO
Bioanalytical Services and Logistical Solutions
Scott Vincent
scott.vincent@a4pbio.com
01304 249107
Alfa Aesar
Research Chemicals, Metals and Materials
Ruth Westwood
ruth.westwood@alfa.com
01763 253147
Cambridge Plant Interiors
Interior Plant Services
Ruscha Fields
ruscha@cambplant.co.uk
07969 881135
Fluorochem
Chemical Intermediates
Lee Jones
leej@fluorochem.co.uk
01457 860111
Holiday Inn Express Cambridge Duxford
Hotel and Conference Accommodation
John Banks
reservationsmrg @hiexpress cambridgeduxford.co.uk
01223 497085
Viadex RCC
IT Infrastructure and Service Solutions
Michael Hills
michael.hills@viadex.com
02087 391811
Our Facilities Management Services Don’t forget that One Nucleus offers management for office and Facilities Management consultancy laboratory fit-outs and can advise to members at a discounted rate. on equipment service contracts, maintenance contracts, cleaning Richard Dickinson richard@ contracts, utility bills, insurance, onenucleus.com or 01223 896453, purchasing and budgeting. One Nucleus' Director of Specialist Services, has over 15 years’ Currently consulting at Cantab experience as a Facilities Manager Biopharmaceuticals, Fahy Gurteen and has worked for more than 20 Laboratories Abzena and Aqdot, years in the life science sector. Richard has previously consulted for a number of One Nucleus members Richard provides project on various projects including Astex
Consultancy Day Rate www.onenucleus.com
Therapeutics, Babraham Bioscience Technologies, Pathology Diagnostics, Zoragen, Origin Sciences, Iontas and Spirogen. Richard can provide help by phone or email as well as providing full onsite consultancy. For further information, please visit http://onenucleus.com/purchasingconsortium
Gold Members
Silver Members
Non Members
£500
£600
£750
Spring 2015 37
One Nucleus News
ON Global - For Life Science Executives Doing Business Globally ON Global connects One Nucleus’s activities to support our members in their domestic and international business endeavours. Conceived to facilitate access by our members to suitable meeting, office and business services whilst away from home on business, ON Hub was the starting point for the ON Global initiative which has now developed into an integrated support network of:
match any price on a bespoke trip, • US and Canadian collaborators you choose the dates, airline and in other key regions including hotel and FBCT undertake to ensure New Jersey, Pennsylvania and they won’t be undersold. British Columbia
ON Meet and Stay – Maximise • European cluster groups from the ease and benefits of knowing hubs including Medicon Valley, what to expect when you book your Stockholm, Uppsala, Munich, accommodation, ensuring you get Heidelberg, Paris and Barcelona access to the locations and services that matter to you. Registering with • Discounted conference Hilton Honors or Club Carlson opens attendance via our United Life up discounts and special offers Sciences partnership, often from these global hotel chains, in collaboration with EBD ON Hub - A growing network of between them coveting almost 100 Group including for example, innovation centre hubs, offering countries. Biotech Showcase. Other executives the opportunity to conference discounts are often access open meeting spaces, WiFi ON Partnerships* – make the available through One Nucleus and refreshment whilst visiting the most of One Nucleus connections relationships with third party region. Contacting the participating with life science clusters and organisers innovation hubs in advance enables Government trade support groups members to use the facilities and around the globe in order to • Connections with Asia Pacific arrange to meet others. Hubs connect with potential partners, groups such as Queensland currently participating cover investors and customers. Benefits Life Sciences, Japanese Biotech London, Cambridge, Wales and include introductions to key Association, C-CAMP in India North West UK. contacts in Europe, North America and KHIDI in Korea and Asia–Pacific countries and ON Travel* – One Nucleus access to information on key • Collaboration with UK Trade Support Supplier, Flight Centre opportunities and intelligence & Investment in order to Business Travel (FCBT), proactively supplied by our international partners. keep our members abreast of negotiates exclusive deals for our engagement opportunities via members on long haul travel and Our collaborators include: the UK Government’s trade accommodation around dates of key support initiatives global Life Science events such as • Our Memorandum of * Member benefit only JP Morgan, Biotech Showcase, BIO Understanding (MOU) partners, Convention and Biopharm America. BIOCOM, BayBio, MassBio and Moreover, leveraging the might of MassMedic on the East and West Director of Business Development the Flight Centre brand, FCBT will Coast US
Life Science Leadership Series Anti-microbial Resistance
Strategies and Funding of Clinical Trials
Inflammation and Immunity
20 May 2015
24 September 2015
11 February 2016
Cambridge, UK onenucleus.com/events
www.onenucleus.com
38 One Nucleus News
Spring 2015
New Members • • • • • • • • • • • • • • • • • •
80th Atom Action for Innovation Limited AECOM Altair Clinical Antibody Resource Artemida Pharma Bio-Analytical Technologies (UK) Ltd BioClone Ltd BTG International Ltd Cambridge Interim HR Ltd Cambridge Plant Interiors Cambridgene Cambridgeshire Chambers of Commerce Capella Bioscience Ltd CELENYS CIMYM BioSciences Ltd CNA Hardy (Life Sciences) Congenica Ltd
• • • • • • • • • • • • • • • • • • • •
Consultant - Dr Deirdre Gillespie Coutts Consulting CS Genetics Drugabilis EBD Group Epsilon Bioconsulting Ltd Eva Diagnostics GlobalData Hadean Ventures HC Pharma Consulting Ltd Health E-Games Ltd High Force Research Ltd Ipsen Development Ltd Jon Torrens LabCorp Clinical Trials Londoneast-UK Ltd Midven Ltd Miti Biosystems Nemesis Bioscience Ltd Nexcelom BioScience Ltd
• NIBSC • OncoLogica UK Ltd • Organisation Effectiveness Cambridge (OE Cam LLP) • Oxford BioTherapeutics Ltd • PharmaGuide Ltd • PharmaVentures Ltd • Preome Ltd • RadBee Ltd • Roslin Cells Ltd • SANOFI • Selectbio • Sort My Events • STEMCELL Technologies UK Ltd • Strem Chemicals UK Ltd • Theradex (Europe) Ltd • Viadex • Wellcome Trust Sanger Institute • Wickham Laboratories Ltd • Wolfson Research
One Nucleus Sponsors Corporate Patron
Corporate Sponsors
Partners
Media Partners www.onenucleus.com
The One Nucleus ON Highlights is written by individuals and is not necessarily a reflection of the views held by One Nucleus.